Deciding how different Sanofi's oral multiple sclerosis therapy Aubagio (teriflunomide) is to a previously marketed medicine split the Committee for Medicinal Products for Human Use (CHMP), with nine members dissenting from the majority view of around 27 members that Aubagio was indeed a new active substance (NAS).
The European Medicines Agency’s top advisory committee had originally decided against granting NAS status to Aubagio when it released a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?